CNO vs JXN

Key Takeaways

• CNO Financial Group and Jackson Financial Inc. both operate in the life and health insurance sector but serve fundamentally different market segments — CNO targets the middle-income demographic while JXN dominates the retail annuity and retirement solutions space.
• JXN delivered adjusted operating earnings per share of $22.67 for full-year 2025, with an adjusted operating return on equity (ROE) of 14.7%, while CNO reported operating EPS of $4.40 and an operating ROE of 11.4%.
• JXN returned $862 million to shareholders in 2025 and raised its quarterly dividend by 12.5% to $0.90 per share for early 2026; CNO returned $386 million to shareholders during the same period.
• In recent analyst actions, Jefferies downgraded CNO to Hold while upgrading JXN to Buy, reflecting shifting sentiment around growth trajectories and capital return profiles.
• Both stocks have received favorable long-term ratings from Tickeron's analytical models, but short-term technical indicators and fundamental scores suggest different near-term positioning.

Introduction

Investors scanning the insurance sector for value and growth frequently encounter two names that warrant a closer look: CNO (CNO Financial Group) and JXN (Jackson Financial Inc.). Both are U.S.-based financial services companies with significant footprints in the life and health insurance industry, yet their strategic focus, scale, and financial profiles diverge in ways that matter for portfolio construction. This stock comparison examines each company's recent performance, business model, and market positioning to help traders and investors understand the trade-offs between a middle-income-focused insurer executing a steady turnaround and a retirement-solutions powerhouse riding strong demographic tailwinds.

CNO Overview and Recent Performance

CNO Financial Group, headquartered in Carmel, Indiana, is a holding company whose subsidiaries — including Bankers Life, Washington National, and Colonial Penn — design and distribute health insurance, life insurance, and annuity products primarily to the middle-income and senior markets across the United States. The company operates through Consumer and Worksite divisions, reaching customers via direct-to-consumer channels, agent networks, and workplace benefit programs.

In recent months, CNO has demonstrated consistent operational momentum. The company posted its 14th consecutive quarter of strong insurance sales growth to close out 2025, with total new annualized premiums (NAP) — a key measure of new business written — rising 15% for the full year, a company record. Operating earnings per share grew 11% year over year, supported by expanding underwriting margins and growing investment income. CNO returned approximately $386 million to shareholders during 2025 through share repurchases and dividends, an 11% increase from the prior year. Management raised its 2027 operating ROE improvement target to 200 basis points above its 2024 baseline, reflecting confidence in strategic actions including a second Bermuda reinsurance transaction and the streamlining of its Worksite fee-services operations. Book value per diluted share, excluding accumulated other comprehensive loss (AOCI), stood at $38.81 at year-end 2025.

JXN Overview and Recent Performance

JXN Jackson Financial Inc., based in Lansing, Michigan, is a leading provider of retirement solutions in the United States. Through its flagship subsidiary Jackson National Life Insurance Company, the firm offers variable annuities, registered index-linked annuities (RILAs), fixed and fixed index annuities, institutional products, and closed-block life and annuity policies. JXN distributes its products through a broad network of independent broker-dealers, banks, wirehouses, registered investment advisors, and insurance agents.

Jackson Financial delivered what management called a "monumental" 2025, with record retail annuity sales of $19.7 billion, up 10% from the prior year. A standout performer was the RILA segment, which posted record sales of $6.9 billion — a 22% year-over-year increase — while institutional product sales surged 77% to $3.5 billion. Adjusted operating earnings reached $1.6 billion, or $22.67 per diluted share, and the company's adjusted operating ROE climbed to 14.7%. JXN's capital position remains robust, with a risk-based capital (RBC) ratio of 567% at its operating subsidiary, well above regulatory minimums. The company returned $862 million to common shareholders in 2025, increased its quarterly dividend by 12.5% to $0.90 per share for early 2026, and established a 2026 capital return target of $900 million to $1.1 billion. A recently announced long-term strategic partnership with TPG, including a $500 million equity investment, further bolsters JXN's growth roadmap in spread-based products.

Trending AI Robots

In a market environment where timely, data-driven decisions are increasingly essential, Tickeron's Trending AI Robots page offers a curated selection of the platform's most relevant AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers across stocks, ETFs, forex, and crypto. However, only those bots demonstrating the strongest alignment with current market conditions earn a spot in the Trending AI Robots section. These bots feature diverse trading styles, strategies, and timeframes — ranging from 5-minute high-frequency agents to 60-minute swing-trading models. Top-performing bots in the Tickeron ecosystem have posted annualized returns ranging from 78% to over 290%, with transparent metrics including Sharpe ratios, drawdown statistics, profit factors, and closed trade logs available for evaluation. Each bot operates with different risk parameters, position-sizing approaches, and ticker-specific focuses, allowing traders to find strategies that match their individual objectives. To explore which bots are currently leading the platform, visit Trending AI Robots.

Head-to-Head Comparison

While both CNO and JXN operate under the life and health insurance umbrella, their business models diverge sharply. CNO focuses on the middle-income market with a mix of health insurance (Medicare supplement, supplemental health, long-term care), life insurance, and modest annuity offerings distributed through a dedicated agent force and direct-response marketing. JXN, by contrast, is an annuity-centric powerhouse whose growth is fueled by retirement savings demand, innovative RILA products, and a robust institutional platform.

In scale, JXN is the larger entity with a market capitalization of approximately $7.6 billion versus CNO's roughly $4.1 billion (based on recent market data). Revenue comparisons are similarly lopsided, with JXN generating roughly $4.75 billion compared to CNO's $4.44 billion, though CNO's revenue base is more diversified across health and life premiums. On profitability, JXN's adjusted operating earnings of $1.6 billion dwarf CNO's $439 million, yet CNO's GAAP net income has been more consistent — JXN's reported net income swung to a modest loss in 2025 due to non-economic accounting impacts from reinsured business and hedging results, factors that do not affect statutory capital or free cash flow.

Capital return strategies also differ. JXN's $862 million in 2025 shareholder returns, including $634 million in buybacks and a dividend now yielding approximately 3.1%, reflects a more aggressive return philosophy aimed at shrinking share count and boosting per-share metrics. CNO's $386 million in returns, while smaller in absolute terms, represents an 11% increase and aligns with its more measured, steady-growth approach. Risk profiles diverge as well: JXN carries higher sensitivity to equity market performance given its variable annuity exposure, while CNO's middle-income health and life focus provides more insulated, though slower, compounding.

Tickeron AI Verdict

Based on observable trend consistency, capital return momentum, and relative market positioning, Tickeron's AI models would likely tilt toward JXN in the current environment — though with important caveats. JXN's adjusted operating ROE of 14.7%, aggressive share buyback program, growing RILA franchise, and the TPG strategic partnership all point to stronger near-term catalysts and return potential. However, CNO's steadier GAAP earnings profile, lower market sensitivity, and improving operational efficiency should not be overlooked by risk-conscious investors. Tickeron's own comparison metrics highlight that CNO scores slightly better on short-term technical indicators (6 bullish versus 3 for JXN), while both receive favorable long-term fundamental ratings. The AI-driven assessment suggests JXN may offer superior momentum-driven opportunity, while CNO represents a more defensive position within the same sector. As always, the most suitable choice depends on an investor's time horizon and risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations